Role of genetic polymorphisms in clopidogrel response variability: a systematic review.

ABSTRACT:

Introduction

Clopidogrel is a P2Y₁₂ inhibitor that has become a mainstay treatment following percutaneous intervention with drug-eluting stent placement to decrease restenosis and its potential complications, including sudden cardiac death and ischaemic strokes in patients with significant vascular disease.

Areas covered

As a prodrug, the metabolism and efficacy of clopidogrel are contingent on the presence of wild-type CYP450 (CYP2C19) alleles. Genetic polymorphisms and variants are well known to impair its ability to prevent major adverse cardiovascular events in these patients, with inadequate response rates as high as 30% in previous publications. Patterns of allelic frequencies are expected to exhibit similarities between individuals of the same ancestry, eth

SUBMITTER: Lopez J 

PROVIDER: S-EPMC10649851 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature